Beximco Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Beximco Pharmaceuticals has a total shareholder equity of BDT50.4B and total debt of BDT6.9B, which brings its debt-to-equity ratio to 13.8%. Its total assets and total liabilities are BDT70.2B and BDT19.8B respectively. Beximco Pharmaceuticals's EBIT is BDT7.8B making its interest coverage ratio 6.9. It has cash and short-term investments of BDT1.7B.
Key information
13.8%
Debt to equity ratio
৳6.95b
Debt
| Interest coverage ratio | 6.9x |
| Cash | ৳1.73b |
| Equity | ৳50.41b |
| Total liabilities | ৳19.81b |
| Total assets | ৳70.22b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BXPHARMA's short term assets (BDT21.8B) exceed its short term liabilities (BDT12.1B).
Long Term Liabilities: BXPHARMA's short term assets (BDT21.8B) exceed its long term liabilities (BDT7.7B).
Debt to Equity History and Analysis
Debt Level: BXPHARMA's net debt to equity ratio (10.3%) is considered satisfactory.
Reducing Debt: BXPHARMA's debt to equity ratio has reduced from 36.7% to 13.8% over the past 5 years.
Debt Coverage: BXPHARMA's debt is well covered by operating cash flow (120.5%).
Interest Coverage: BXPHARMA's interest payments on its debt are well covered by EBIT (6.9x coverage).